HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright also issued estimates for Immunic's Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.74) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.06) EPS.

Several other analysts have also issued reports on the stock. StockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. D. Boral Capital reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Immunic in a research note on Thursday, April 10th. Finally, William Blair started coverage on Immunic in a research report on Tuesday, March 25th. They set an "outperform" rating on the stock. One analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $13.20.

Immunic Price Performance

Immunic stock traded up $0.04 during mid-day trading on Tuesday, reaching $0.98. 215,076 shares of the stock traded hands, compared to its average volume of 625,966. The stock has a market capitalization of $93.90 million, a PE ratio of -0.80 and a beta of 1.91. The business's 50-day moving average is $1.08 and its 200-day moving average is $1.14. Immunic has a 12-month low of $0.83 and a 12-month high of $2.11.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. State Street Corp lifted its position in shares of Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after buying an additional 11,642 shares in the last quarter. 683 Capital Management LLC increased its position in Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock valued at $700,000 after acquiring an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC raised its stake in shares of Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after acquiring an additional 22,200 shares during the period. Focus Partners Wealth lifted its holdings in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after acquiring an additional 23,610 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Immunic during the 3rd quarter worth about $50,000. Institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.